Search

Your search keyword '"Sánchez-Arias, Juan Antonio"' showing total 11 results
Start Over Author "Sánchez-Arias, Juan Antonio"
11 results on '"Sánchez-Arias, Juan Antonio"'

1. Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with In Vivo Efficacy in Multiple Myeloma

Author

Rabal, Obdulia, primary, San José-Enériz, Edurne, additional, Agirre, Xabier, additional, Sánchez-Arias, Juan Antonio, additional, de Miguel, Irene, additional, Ordoñez, Raquel, additional, Garate, Leire, additional, Miranda, Estíbaliz, additional, Sáez, Elena, additional, Vilas-Zornoza, Amaia, additional, Pineda-Lucena, Antonio, additional, Estella, Ander, additional, Zhang, Feifei, additional, Wu, Wei, additional, Xu, Musheng, additional, Prosper, Felipe, additional, and Oyarzabal, Julen, additional

Published
2021
Full Text
View/download PDF

4. Amylin as a potential link between type 2 diabetes and alzheimer disease

Author

Martinez‐Valbuena, Ivan, primary, Valenti‐Azcarate, Rafael, additional, Amat‐Villegas, Irene, additional, Riverol, Mario, additional, Marcilla, Irene, additional, Andrea, Carlos E., additional, Sánchez‐Arias, Juan Antonio, additional, Mar Carmona‐Abellan, Maria, additional, Marti, Gloria, additional, Erro, Maria‐Elena, additional, Martínez‐Vila, Eduardo, additional, Tuñon, Maria‐Teresa, additional, and Luquin, Maria‐Rosario, additional

Published
2019
Full Text
View/download PDF

5. Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy

Author

Rabal, Obdulia, primary, San José-Enériz, Edurne, additional, Agirre, Xabier, additional, Sánchez-Arias, Juan Antonio, additional, Vilas-Zornoza, Amaia, additional, Ugarte, Ana, additional, de Miguel, Irene, additional, Miranda, Estíbaliz, additional, Garate, Leire, additional, Fraga, Mario, additional, Santamarina, Pablo, additional, Fernandez Perez, Raul, additional, Ordoñez, Raquel, additional, Sáez, Elena, additional, Roa, Sergio, additional, García-Barchino, María José, additional, Martínez-Climent, José Angel, additional, Liu, Yingying, additional, Wu, Wei, additional, Xu, Musheng, additional, Prosper, Felipe, additional, and Oyarzabal, Julen, additional

Published
2018
Full Text
View/download PDF

6. Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces

Author

Rabal, Obdulia, primary, Sánchez-Arias, Juan Antonio, additional, San José-Enériz, Edurne, additional, Agirre, Xabier, additional, de Miguel, Irene, additional, Garate, Leire, additional, Miranda, Estibaliz, additional, Sáez, Elena, additional, Roa, Sergio, additional, Martínez-Climent, José Angel, additional, Liu, Yingying, additional, Wu, Wei, additional, Xu, Musheng, additional, Prosper, Felipe, additional, and Oyarzabal, Julen, additional

Published
2018
Full Text
View/download PDF

10. Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with In VivoEfficacy in Multiple Myeloma

Author

Rabal, Obdulia, San José-Enériz, Edurne, Agirre, Xabier, Sánchez-Arias, Juan Antonio, de Miguel, Irene, Ordoñez, Raquel, Garate, Leire, Miranda, Estíbaliz, Sáez, Elena, Vilas-Zornoza, Amaia, Pineda-Lucena, Antonio, Estella, Ander, Zhang, Feifei, Wu, Wei, Xu, Musheng, Prosper, Felipe, and Oyarzabal, Julen

Abstract

Concomitant inhibition of key epigenetic pathways involved in silencing tumor suppressor genes has been recognized as a promising strategy for cancer therapy. Herein, we report a first-in-class series of quinoline-based analogues that simultaneously inhibit histone deacetylases (from a low nanomolar range) and DNA methyltransferase-1 (from a mid-nanomolar range, IC50< 200 nM). Additionally, lysine methyltransferase G9a inhibitory activity is achieved (from a low nanomolar range) by introduction of a key lysine mimic group at the 7-position of the quinoline ring. The corresponding epigenetic functional cellular responses are observed: histone-3 acetylation, DNA hypomethylation, and decreased histone-3 methylation at lysine-9. These chemical probes, multitarget epigenetic inhibitors, were validated against the multiple myeloma cell line MM1.S, demonstrating promising in vitroactivity of 12a(CM-444) with GI50of 32 nM, an adequate therapeutic window (>1 log unit), and a suitable pharmacokinetic profile. In vivo, 12aachieved significant antitumor efficacy in a xenograft mouse model of human multiple myeloma.

Published
2021
Full Text
View/download PDF

11. Interictal amylin levels in chronic migraine patients: A case-control study.

Author

Irimia, Pablo, Martínez-Valbuena, Iván, Mínguez-Olaondo, Ane, Domínguez-Vivero, Clara, Sánchez-Arias, Juan-Antonio, Martínez-Vila, Eduardo, Luquin, María-Rosario, and Leira, Rogelio

Subjects
*AMYLIN, *CALCITONIN gene-related peptide, *MIGRAINE, *CLUSTER headache, *BODY mass index, *CASE-control method
Abstract

Background: Recently, amylin and its receptors were found in different structures involved in migraine pathophysiology. Here, we evaluate interictal concentrations of amylin and calcitonin gene-related peptide in peripheral blood as biomarkers for chronic migraine. Methods: We prospectively recruited patients with episodic migraine, chronic migraine and healthy controls. Interictal amylin and calcitonin gene-related peptide levels were assessed in blood samples using enzyme linked immunosorbent assay. Results: We assessed plasma samples from 58 patients with episodic migraine (mean age 37.71 ± 10.47, 87.9% female), 191 with chronic migraine (mean age 46.03 ± 11.93, 95% female), and on 68 healthy controls (mean age 43.58 ± 11.08 years, 86% female). Body mass index was 25.94 ± 4.53 kg/m2 for migraine patients and 25.13 ± 4.92 kg/m2 for healthy controls (p = 0.0683). Interictal plasma amylin levels were higher in chronic migraine patients (47.1 pg/mL) than in the episodic migraine patients (28.84 pg/mL, p < 0.0001) and healthy controls (24.74 pg/mL, p < 0.0001). Plasma calcitonin gene-related peptide levels were increased (20.01 pg/mL) in chronic migraine patients when compared to healthy controls (11.37 pg/mL, p = 0.0016), but not to episodic migraine patients (18.89 pg/mL, p = 0.4369). Applying a cut-off concentration of 39.68 pg/mL plasma amylin, the sensitivity to differentiate chronic migraine from healthy controls was 57.6% and the specificity was 88.2%. Variables such as age, analgesic overuse, depression, allodynia, use of preventive medication or a history of aura did not influence the plasma concentrations of amylin or calcitonin gene-related peptide. Conclusion: Interictal plasma amylin levels are higher in patients with chronic migraine and may serve as a diagnostic biomarker for chronic migraine. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results